Peter A. Kiener, D.Phil., President and CEO

Prior to starting Zyngenia, Dr. Kiener's most recent position was at AstraZeneca PLC/MedImmune, LLC as Executive vice President and Global Head of Biologics and R&D. During eight years at MedImmune as Executive Vice President and Head of Research and Development, Dr. Kiener helped build industry-leading protein and antibody engineering capabilities and oversaw the submission of multiple INDs and NDAs. Dr. Kiener was also responsible for the integration of both the protein/antibody engineering company Cambridge Antibody Technology and the B-cell biologics company Cellective Therapeutics into MedImmune. Before working at MedImmune, he spent 18 years at Bristol-Myers Squibb, ten of which were spent working on biological therapeutics. During his tenure at MedImmune, Dr. Kiener was also a member of the MedImmune Ventures investment committee and was actively involved in growing the organization’s venture portfolio. Dr. Kiener currently serves as Chairman of the board of Resolve Therapeutics and previously served on three boards: Receptor Biologix, Synovex Inc. and Virdante Pharmaceuticals. He currently serves on the scientific advisory boards of KAI, Genocea, and NKT Therapeutics. Dr. Kiener received his B.A. in Chemistry from the University of Lancaster, UK, and his D. Phil. in Biochemistry from Oxford University, UK . Dr. Kiener has published more than 115 papers in peer-reviewed journals, and is an inventor on more than 30 patents and patent applications.